Yükleniyor... / Loading...
This study compares the drug Galcanezumab (LY2951742, a CGRP antibody) with placebo in patients with migraine headache. It included patients with at least 1 year of migraine history whose migraines began before age 50. It was a Phase 2 study and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Participants with a history of migraine of at least 1 year prior to enrollment. * Migraine onset prior to age 50. Exclusion Criteria: * Current enrollment in, or discontinuation within the last 30 days from, a clinical trial involving any investigational drug or device. * Current use or any prior exposure to any CGRP antibody, any antibody to the CGRP receptor, or antibody to nerve growth factor (NGF). * History of migraine subtypes including hemiplegic migraine, ophthalmoplegic migraine, and basilar-type migraine. * Have a history or presence of other medical illness that indicates a medical problem that would preclude study participation. * Failure to respond to more than two adequately dosed effective migraine prevention treatments. * Evidence of significant active psychiatric disease, in the opinion of the investigator. * Women who are pregnant or nursing.